Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Giancarlo Castaman, Michiel Coppens & Steven W Pipe. (2023) Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B. Expert Review of Hematology 0:0, pages 1-14.
Read now
Read now
Jennifer Quinn, Kathleen A Delaney, Wing Yen Wong, Wolfgang Miesbach & Monika Bullinger. (2022) Psychometric Validation of the Haemo-QOL-A in Participants with Hemophilia A Treated with Gene Therapy. Patient Related Outcome Measures 13, pages 169-180.
Read now
Read now
Tom Burke, Anum Shaikh, Talaha M. Ali, Nanxin Li, Randall Curtis, Daniel-Anibal Garcia Diego, Michael Recht, Thomas Sannie, Mark Skinner & Jamie O’Hara. (2022) Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. Journal of Medical Economics 25:1, pages 386-392.
Read now
Read now
Martin Olivieri, Mindy Simpson, Songkai Yan, Johanna Fedorovsky, Xiang Zhang, Radovan Tomic, Karen Pinachyan & Maria Elisa Mancuso. (2022) Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A. Current Medical Research and Opinion 38:7, pages 1133-1139.
Read now
Read now
Barbara A Konkle, Doris V Quon, Leslie Raffini, Michael Recht, Vlad C Radulescu, Shannon L Carpenter, Amy L Dunn, Mei Lu & Maureen Watt. (2021) A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). Journal of Blood Medicine 12, pages 883-896.
Read now
Read now
Cassandra P. Wang, Guy Young & Courtney D. Thornburg. (2021) Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opinion on Drug Safety 20:4, pages 387-396.
Read now
Read now
Nanxin Li, Eileen K. Sawyer, Konrad Maruszczyk, Greg Guzauskas, Marta T. Slomka, Tom Burke, Antony P. Martin, Jamie O’Hara, Matt Stevenson & Michael Recht. (2021) Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal of Medical Economics 24:1, pages 363-372.
Read now
Read now
Ana Torres-Ortuño, Rubén Cuesta-Barriuso, Joaquín Nieto-Munuera, Álvaro Castiello-Munuera, Manuel Moreno-Moreno & José Antonio López-Pina. (2020) Haemo-Adhaesione: A New Measure of Adherence for Adolescent and Adult Patients with Haemophilia. Patient Preference and Adherence 14, pages 455-465.
Read now
Read now
Lukas Graf, Songkai Yan, Ming-Ching Shen & Vinod Balasa. (2020) A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A. Journal of Medical Economics 23:12, pages 1493-1498.
Read now
Read now
Sarah Bérubé, Émélie Rondeau & Serge Sultan. (2019) Measuring adherence in pediatric hemophilia patients: French-language adaptation of the VERITAS-Pro and VERITAS-PRN and psychometric properties. Cogent Medicine 6:1.
Read now
Read now
Giancarlo Castaman. (2018) The benefits of prophylaxis in patients with hemophilia B. Expert Review of Hematology 11:8, pages 673-683.
Read now
Read now
Articles from other publishers (78)
Steven W. Pipe, Valder R. Arruda, Claudia Lange, Stephen Kitchen, Hermann Eichler & Samuel Wadsworth. (2023) Characteristics of BAY 2599023 in the Current Treatment Landscape of
Hemophilia A Gene Therapy. Current Gene Therapy 23:2, pages 81-95.
Crossref
Crossref
George M. Solomon, Alan F. BarkerElizabeth McSpiritt, Sonja Marikovics, Alexandra L. Quittner, Alan F. Barker, Charles Daley, Leigh Anne Daniels, Jodie Jones, Pamela McShane, Alexandra Quittner, George M. Solomon, Kevin Winthrop, Patricia Walker, Sebastian Kurz, Louis DePalo, Charles Haworth, Richard Belkin, Charles L. Daley, Joseph Khabbaza & Elliott Dasenbrook. (2023) Pilot Evaluation of a Management Toolkit for Airway Clearance Therapy in Bronchiectasis (IMPACT BE). ATS Scholar 4:1, pages 76-86.
Crossref
Crossref
Chia-Yau Chang, Shiue-Wei Lai, Mei-Mei Cheng, Jung-Tzu Ku, Shu-Hsia Hu, Yen-Lin Liu, Jia-Ruey Tsai, Chen-Hua Tsai, Chao-Neng Cheng & Yeu-Chin Chen. (2022) Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy. International Journal of Hematology 117:3, pages 378-387.
Crossref
Crossref
Theresa Ukamaka Nwagha, Helen Chioma Okoye, Saleh Yuguda, Christiana Enefiok Udo, Mutiat Kehinde Ogunfemi, Dalhat Haliru Gwarzo & Nnamdi Joel Osuji. (2023) Adherence to prophylaxis and bleeding outcome: A multicenter Nigerian study. PLOS ONE 18:2, pages e0264600.
Crossref
Crossref
Mark T. Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth & Cedric Hermans. (2023)
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities:
post hoc
analysis from the PROTECT VIII study
. Therapeutic Advances in Hematology 14, pages 204062072311667.
Crossref
Crossref
Jan Astermark, Jan Blatný, Christoph Königs, Cédric Hermans, Victor Jiménez-Yuste & Daniel P. Hart. (2023) Considerations for shared decision management in previously untreated patients with hemophilia A or B. Therapeutic Advances in Hematology 14, pages 204062072311658.
Crossref
Crossref
Annarita Tagliaferri, Angelo Claudio Molinari, Flora Peyvandi, Antonio Coppola, Francesco Demartis, Chiara Biasoli, Alessandra Borchiellini, Dorina Cultrera, Raimondo De Cristofaro, Filomena Daniele, Paola Giordano, Emanuela Marchesini, Maurizio Margaglione, Renato Marino, Berardino Pollio, Paolo Radossi, Cristina Santoro, Rita Carlotta Santoro, Sergio Siragusa, Gianluca Sottilotta, Alberto Tosetto, Lydia Piscitelli, Maria Rosaria Villa, Ezio Zanon, Adele Finardi, Irene Schiavetti, Daniella Vaccari & Giancarlo Castaman. (2022) IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy. Haemophilia 29:1, pages 135-144.
Crossref
Crossref
Anupam Dutta, Dipjyoti Boruah, Angshuman Boruah & Arijit Das. (2023) Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia. Annals of the National Academy of Medical Sciences (India) 59:01, pages 021-026.
Crossref
Crossref
Michael A. Nardi. 2023.
273
315
.
N Gallastegui, BUK Steiner, P Aguero, C Bailey, R Kruse-Jarres, DV Quon, C Hanacek, LM Volland, RFW Barnes & A von Drygalski. (2022) The role of point-of-Care Musculoskeletal Ultrasound for Routine Joint evaluation and management in the Hemophilia Clinic - A Real World Experience. BMC Musculoskeletal Disorders 23:1.
Crossref
Crossref
Ramiro Núñez, María Teresa Álvarez-Román, Santiago Bonanad, José Ramón González-Porras, Hortensia De La Corte-Rodriguez, Rubén Berrueco & Víctor Jiménez-Yuste. (2022) The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients. TH Open 06:04, pages e365-e377.
Crossref
Crossref
Natasha Fosker, Alejandra Anderson, Laura Morton & Andrea Pisa. (2022) Can Behavioural Science Be the Key to Unlocking Patient Adherence? Evidence-Led Development of an Engaging Digital Health Solution. Proceedings of the International Symposium on Human Factors and Ergonomics in Health Care 11:1, pages 38-43.
Crossref
Crossref
Maria Elisa Mancuso, Sheila J. M. Ingham & Marc Kunze. (2022) Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis. Haemophilia 28:5, pages 702-712.
Crossref
Crossref
Anum Shaikh, Gabriel Pedra, Matthew Cawson & Catherine Wiseman. (2022) Examining the impact of haemophilia treatment on health‐related quality of life. Haemophilia 28:5, pages 796-805.
Crossref
Crossref
Christoph Königs, Margareth C. Ozelo, Amy Dunn, Roshni Kulkarni, Beatrice Nolan, Simon A. Brown, Michele Schiavulli, Sriya Gunawardena, Sutirtha Mukhopadhyay, Deepthi Jayawardene, Bent Winding & Manuel Carcao. (2022) First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood 139:26, pages 3699-3707.
Crossref
Crossref
Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupančić-Šalek, Johannes Oldenburg & Pratima Chowdary. (2022) Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Advances 6:11, pages 3422-3432.
Crossref
Crossref
Yin Ting Cheung, Pok Hong Lam, Henry Hon Wai Lam, Chung-Tin Ma, Alex Wing Kwan Leung, Raymond Siu Ming Wong & Chi Kong Li. (2022) Treatment Adherence and Health-Related Quality of Life in Patients with Hemophilia in Hong Kong. International Journal of Environmental Research and Public Health 19:11, pages 6496.
Crossref
Crossref
Toshko Lissitchkov, Annemieke Willemze, Suresh Katragadda, Kara Rice, Stacey Poloskey & Craig Benson. (2022) Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Advances 6:4, pages 1089-1094.
Crossref
Crossref
Guendalina Graffigna, Serena Barello, Caterina Bosio, Chiara Biasoli, Andrea Buzzi, Cristina Cassone, Luigi Ambroso, Patrizia Di Gregorio, Lorenzo Farace, Paola Giordano, Renato Marino, Irene Ricca & Angiola Rocino. (2022) Health Policy Brief: i pilastri dell’Engagement in Emofilia. AboutOpen 9, pages 3-9.
Crossref
Crossref
Richard A Wilkins, David Stephensen, Heidi Siddle, Martin J Scott, Hua Xiang, Elizabeth Horn, Ben Palmer, Graham J Chapman, Michael Richards, Rebecca Walwyn & Anthony Redmond. (2022) Twelve-month prevalence of haemarthrosis and joint disease using the Haemophilia Joint Health score: evaluation of the UK National Haemophilia Database and Haemtrack patient reported data: an observational study. BMJ Open 12:1, pages e052358.
Crossref
Crossref
Fadzlin Mohd Mokhtar, Jameela Sathar & Hasniza Zaman Huri. (2021) Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention. Healthcare 9:12, pages 1702.
Crossref
Crossref
Tom Burke, Sohaib Asghar, Jamie O’Hara, Margaret Chuang, Eileen K. Sawyer & Nanxin Li. (2021) Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Jing Sun, Xuan Zhou & Nan Hu. (2021) Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Tom Burke, Sohaib Asghar, Jamie O’Hara, Eileen K. Sawyer & Nanxin Li. (2021) Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Dide Okaygoun, Danielle D. Oliveira, Sooriya Soman & Riccardo Williams. (2021) Advances in the management of haemophilia: emerging treatments and their mechanisms. Journal of Biomedical Science 28:1.
Crossref
Crossref
Louis P. Garrison, Ed Pezalla, Adrian Towse, Hongbo Yang, Elizabeth Faust, Eric Q. Wu, Nanxin Li, Eileen K. Sawyer & Michael Recht. (2021) Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value in Health 24:11, pages 1628-1633.
Crossref
Crossref
Martin Sanabria, María Teresa Álvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Johannes Oldenburg, Sabine Friedl & M T Reding. (2021) Design of the HEM-POWR study: a prospective, observational study of
real-world treatment with damoctocog alfa pegol in patients with haemophilia
A. BMJ Open 11:9, pages e044997.
Crossref
Crossref
Michelle Witkop, George Morgan, Jamie O'Hara, Michael Recht, Tyler W. Buckner, Diane Nugent, Randall Curtis, Brian O'Mahony, Mark W. Skinner, Brendan Mulhern, Matthew Cawson, Talaha M. Ali, Eileen K. Sawyer & Nanxin Li. (2021) Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. Haemophilia 27:5, pages 769-782.
Crossref
Crossref
Omotola O Olasupo, Megan S Lowe, Ashma Krishan, Peter Collins, Alfonso Iorio & Davide Matino. (2021) Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. Cochrane Database of Systematic Reviews 2021:8.
Crossref
Crossref
Noemi Dirzu, Ionut Hotea, Ciprian Jitaru, Melen Brinza, Laura Urian, Mareike-Catrina Peters, Krisztina Gal, Louis Popescu, Cristina Blag, Mirela Marian, Eva Pal, Marilena Stanescu, Diana Cenariu, Cristina Tarniceriu, Margit Serban, Delia Dima, Daniel Coriu & Ciprian Tomuleasa. (2021) Mobile Health Technology for the Personalized Therapy of Hemophilia. Frontiers in Medicine 8.
Crossref
Crossref
Guy Young. (2021) Management of children with hemophilia A: How emicizumab has changed the landscape. Journal of Thrombosis and Haemostasis 19:7, pages 1629-1637.
Crossref
Crossref
Margareta Holmström, Elsa Olsson, Jan Astermark, Malin Axelsson, Anna Olsson, Linda Myrin Westesson, Aletta Falk, Johan Szamosi & Karin Sennfält. (2021) Real‐world prophylactic usage of recombinant factor VIII Fc in Sweden: A report from the Swedish national registry for bleeding disorders. Haemophilia 27:4.
Crossref
Crossref
Young Shil Park, Tai Ju Hwang, Goon Jae Cho, Soon Ki Kim, Sang Kyu Park, Ji Yoon Kim, Hee Jo Baek, Young‐Joo Kim, Ho‐Jin Lee, Ji‐Soo Shin, Chung‐Mo Nam, Jiyu Sun & Ki Young Yoo. (2021) Patients’ and parents’ satisfaction with, and preference for, haemophilia A treatments: a cross‐sectional, multicentre, observational study. Haemophilia 27:4, pages 563-573.
Crossref
Crossref
Melody Benton, Anisha M. Patel, Lizheng Shi, Alisha Monnette, Dongzhe Hong, Rebecca Kruse‐Jarres & Karina Raimundo. (2020) Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment. Haemophilia 27:4.
Crossref
Crossref
Suresh Katragadda, Srividya Neelakantan, Lei Diao & Nancy Wong. (2021) Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects. The Journal of Clinical Pharmacology 61:7, pages 889-900.
Crossref
Crossref
Maria Sol Cruz, Josefina Santillan, Julieta Lesser, Juan Pablo Ortiz & Laura Forzani. (2021) Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes. Clinics and Practice 11:2, pages 287-292.
Crossref
Crossref
Victoire Pitance, Stéphanie Désage, Anne Lienhart, Sandrine Meunier & Valérie Chamouard. (2021) Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa. Haemophilia 27:3.
Crossref
Crossref
Michael U. CallaghanClaude Negrier, Ido Paz-PrielTiffany ChangSammy ChebonMichaela LehleJohnny MahlanguGuy Young, Rebecca Kruse-JarresMaria Elisa Mancuso, Markus NiggliMonet HowardNives Selak BienzMidori ShimaVictor Jiménez-Yuste, Christophe SchmittElina AsikaniusGallia G. LevySteven W. Pipe & Johannes Oldenburg. (2021) Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood 137:16, pages 2231-2242.
Crossref
Crossref
Alexandre Jorge Teixeira Ribeiro, Fábio Ferreira Amorim, Beatriz Mac Dowell Soares, Levy Aniceto Santana & Aline Mizusaki Imoto. (2021) Functional and joint evaluation in a prospective cohort of patients with severe haemophilia. Haemophilia 27:2, pages 314-320.
Crossref
Crossref
Nidhi Bhatt, Lisa Boggio & Mindy L. Simpson. (2021) Using an educational intervention to assess and improve disease‐specific knowledge and health literacy and numeracy in adolescents and young adults with haemophilia A and B. Haemophilia 27:2, pages 229-236.
Crossref
Crossref
Christine Kempton, Peter Trask, Aric Parnes, Markus Niggli, Avrita Campinha‐Bacote, Michael Callaghan, Niamh O'Connell, Ido Paz‐Priel & Johnny N. Mahlangu. (2021) Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia 27:2, pages 221-228.
Crossref
Crossref
Zalmai Hakimi, Elena Santagostino, Maarten J. Postma & Jameel Nazir. (2020) Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison. Advances in Therapy 38:2, pages 1263-1274.
Crossref
Crossref
RafalRaad Al-Janabi, AfrahA Salih & MohammedJ Alwan. (2021) Evaluation of efficacy of twice-weekly prophylactic treatment with BeneFIX® (recombinant factor IX) followed by once weekly in children with severe hemophilia B: Six-year data from a local registry. Iraqi Journal of Hematology 10:1, pages 59.
Crossref
Crossref
Anisha M. Patel, Wendy E. Owens, Kathleen Poulos, Karina Raimundo, Gabriel Wong, Janet Bernard, Janet Powers & Richard H. Ko. (2021) Haemophilia A management with emicizumab: A survey of haematologists in the United States. The Journal of Haemophilia Practice 8:1, pages 155-182.
Crossref
Crossref
Kara Garner, Christine Guelcher & Debra Pollard. (2021) The use of rIX-FP in patients with haemophilia B: a nurse's perspective. The Journal of Haemophilia Practice 8:1, pages 86-97.
Crossref
Crossref
Glenn F. Pierce, Assad Haffar & Donna Coffin. (2021) Impact of humanitarian aid linked prophylaxis in Côte d'Ivoire (Ivory Coast). Haemophilia 27:1, pages 9-11.
Crossref
Crossref
Catherine Lambert, N'Dogomo Meité, Ibrahima Sanogo, Sébastien Lobet & Cedric Hermans. (2020) Feasibility and outcomes of low‐dose and low‐frequency prophylaxis with recombinant extended half‐life products (Fc‐rFVIII and Fc‐rFIX) in Ivorian children with hemophilia: Two‐year experience in the setting of World Federation of Haemophilia humanitarian aid programme. Haemophilia 27:1, pages 33-40.
Crossref
Crossref
Benoît Polack, Marc Trossaërt, Mathias Cousin, Sandrine Baffert, Alexandra Pruvot & Chloé Godard. (2020) Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France. Haemophilia 27:1.
Crossref
Crossref
Anshu Shrestha, Jun Su, Nanxin Li, Christopher Barnowski, Nisha Jain, Katie Everson, Anupam Bapu Jena & Katharine Batt. (2021) Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors. Research and Practice in Thrombosis and Haemostasis 5:1, pages 94-103.
Crossref
Crossref
Sylvia von Mackensen, Yves Douma & Susan Halimeh. (2020) Evaluation of the U.S. Adherence Questionnaires VERITAS-PRO and VERITAS-PRN for Use in Patients with Hemophilia in the German Healthcare System. Hämostaseologie 40:05, pages 621-630.
Crossref
Crossref
Andreas Tiede, Santiago Bonanad, Amparo Santamaria, Georg Goldmann, Mariana Canaro, Antonio Palomero, Luis J. G. Frade, Juan Eduardo Megias‐Vericat, Fernanda Martinez, Faustino Garcia Candel, Victor Jimenez Yuste, Monika Sparber‐Sauer, Susan Halimeh, Daniela Adolf, Martin Hukauf, Jan Reichmann & Johannes Oldenburg. (2020) Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary. Haemophilia 26:6, pages 999-1008.
Crossref
Crossref
Shannon L. Meeks & Sébastien Lacroix‐Desmazes. (2020) Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy. Haemophilia 26:6, pages 958-965.
Crossref
Crossref
Alexander Solms, Anita Shah, Erik Berntorp, Andreas Tiede, Alfonso Iorio, Camila Linardi, Maurice Ahsman, Maria Elisa Mancuso, Tihomir Zhivkov & Toshko Lissitchkov. (2020) Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology 99:11, pages 2689-2698.
Crossref
Crossref
Timothy C. Nichols, Howard Levy, Elizabeth P. Merricks, Robin A. Raymer & Martin L. Lee. (2020) Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa. PLOS ONE 15:10, pages e0240896.
Crossref
Crossref
Songkai YanGéraldine S. MaroVidhi DesaiMindy L. Simpson. (2020) A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1258-1265.
Crossref
Crossref
María A. Acosta-Aragón, Angélica R. Álvarez-Mina, Julián C. Velásquez-Paz & Jennifer C. Vizcaíno-Carruyo. (2020) Hemofilia B o enfermedad de Christmas. Medicina y Laboratorio 24:4, pages 273-289.
Crossref
Crossref
Barbara A. KonkleAmy D. ShapiroDoris V. QuonJanice M. StaberRoshni KulkarniMargaret V. RagniEkta S. ChhabraStacey PoloskeyKara RiceSuresh KatragaddaDan RudinJoachim FruebisCraig C. Benson. (2020) BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. New England Journal of Medicine 383:11, pages 1018-1027.
Crossref
Crossref
Santiago Bonanad, María García‐Dasí, José A. Aznar, María Eva Mingot‐Castellano, Victor Jiménez‐Yuste, MªVictoria Calle, Antonio Palma, María Fernanda López‐Fernández, Pascual Marco, María José Paloma, Nuria Fernández‐Mosteirin, Bernat Galmés, Martín Sanabria & MªPilar Álvarez. (2020) Adherence to prophylaxis in adult patients with severe haemophilia A. Haemophilia 26:5, pages 800-808.
Crossref
Crossref
Nathan Visweshwar, Yumeng Zhang, Hazina Joseph, Michael Jaglal & Irmel Ayala. (2020) Chronic pain in patients with hemophilia: is it preventable?. Blood Coagulation & Fibrinolysis 31:6, pages 346-352.
Crossref
Crossref
Maria Elisa Mancuso, Johannes Oldenburg, Lisa Boggio, Gili Kenet, Anthony Chan, Carmen Altisent, Wilfried Seifert & Elena Santagostino. (2020) High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice. Haemophilia 26:4, pages 637-642.
Crossref
Crossref
Cedric Hermans, Renato Marino, Catherine Lambert, Sarah Mangles, Patrick Sommerer, Vincent Rives, Geraldine Maro & Giuseppe Malcangi. (2020) Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis. Advances in Therapy 37:6, pages 2988-2998.
Crossref
Crossref
Kateřina Ratajová, Jan Blatný, Iva Poláčková Šolcová, Zdeněk Meier, Tekla Horňáková, Robert Brnka & Peter Tavel. (2020) Social support and resilience in persons with severe haemophilia: An interpretative phenomenological analysis. Haemophilia 26:3.
Crossref
Crossref
Jayashree Motwani, Benoit Guillet, Jan Blatny, Freimut H. Schilling, Bénédicte Wibaut, Jimena Goldstine, Andras Nagy, Jennifer Doralt, Werner Engl, Srilatha Tangada & Gerald Spotts. (2020) Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A. Haemophilia 26:3, pages 478-486.
Crossref
Crossref
Louis AledortScott MilliganMaureen WattJason Booth. (2020) A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. Journal of Managed Care & Specialty Pharmacy 26:4, pages 492-503.
Crossref
Crossref
Amit Chhabra, Dean Spurden, Patrick F. Fogarty, Bartholomew J. Tortella, Emily Rubinstein, Simon Harris, Andreas M. Pleil, Jennifer Mellor, Jonathan de Courcy & José Alvir. (2020) Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagulation & Fibrinolysis 31:3, pages 186-192.
Crossref
Crossref
Nevine Gamal Andrawes, Manal Hashem Fayek, Nouran Salah El‐Din & Raguia Atef Mostafa. (2019) Effect of low‐dose factor VIII prophylaxis therapy on bone mineral density and 25(OH) vitamin D level in children with severe haemophilia A. Haemophilia 26:2, pages 325-332.
Crossref
Crossref
Christopher C. Lamb, Yunmei Wang & Kalle Lyytinen. (2019) Shared decision making: Does a physician's decision‐making style affect patient participation in treatment choices for primary immunodeficiency?. Journal of Evaluation in Clinical Practice 25:6, pages 1102-1110.
Crossref
Crossref
Jane R. Wells, Adam Gater, Chris Marshall, Theo Tritton, Parth Vashi & Sophia Kessabi. (2019) Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII). The Patient - Patient-Centered Outcomes Research 12:6, pages 611-619.
Crossref
Crossref
Erna C. Balen, Marian Krawczyk, Deborah Gue, Shannon Jackson, Samantha C. Gouw, Johanna G. Bom & Richard Sawatzky. (2019) Patient‐centred care in haemophilia: Patient perspectives on visualization and participation in decision‐making. Haemophilia 25:6, pages 938-945.
Crossref
Crossref
Helmut Glantschnig, Alexander Bauer, Karima Benamara, Michael Dockal, Veronika Ehrlich, Herbert Gritsch, Gerald Höbarth, Frank M. Horling, Alexandra Kopic, Peter Leidenmühler, Birgit M. Reipert, Hanspeter Rottensteiner, Tanja Ruthsatz, Gerald Schrenk, Maria Schuster, Peter L. Turecek, Alfred Weber, Martin Wolfsegger, Friedrich Scheiflinger & Werner Höllriegl. (2019) Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys. Journal of Pharmacology and Experimental Therapeutics 371:1, pages 95-105.
Crossref
Crossref
Chur Woo You, Hee Jo Baek, Sang Kyu Park, Young Shil Park, Ho-Jin Shin, Werner Engl & Srilatha Tangada. (2019) Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients. BLOOD RESEARCH 54:3, pages 198-203.
Crossref
Crossref
Vanessa Giroto Guedes, José Eduardo Corrente, Albert Farrugia, Sylvia Thomas, Patrick Alexander Wachholz & Edison Iglesias Oliveira Vidal. (2019) Comparing objective and self‐reported measures of adherence in haemophilia. Haemophilia 25:5, pages 821-830.
Crossref
Crossref
Anita Shah, Alexander Solms, Sara Wiegmann, Maurice Ahsman, Erik Berntorp, Andreas Tiede, Alfonso Iorio, Maria Elisa Mancuso, Tihomir Zhivkov & Toshko Lissitchkov. (2019) Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology 98:9, pages 2035-2044.
Crossref
Crossref
E. Carlos Rodriguez-Merchan & Leonard A. Valentino. (2019) Emicizumab: Review of the literature and critical appraisal. Haemophilia 25:1, pages 11-20.
Crossref
Crossref
Fadi Nossair & Courtney D. Thornburg. (2018) The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. Therapeutic Advances in Hematology 9:8, pages 239-249.
Crossref
Crossref
Noémie Resseguier, Natacha Rosso-Delsemme, Any Beltran Anzola, Karine Baumstarck, Vanessa Milien, Laurent Ardillon, Sophie Bayart, Claire Berger, Marie-Anne Bertrand, Christine Biron-Andreani, Annie Borel-Derlon, Sabine Castet, Pierre Chamouni, Ségolène Claeyssens Donadel, Emmanuelle De Raucourt, Dominique Desprez, Céline Falaise, Birgit Frotscher, Valérie Gay, Jenny Goudemand, Yves Gruel, Benoît Guillet, Annie Harroche, Abel Hassoun, Yoann Huguenin, Thierry Lambert, Aurélien Lebreton, Anne Lienhart, Michèle Martin, Sandrine Meunier, Fabrice Monpoux, Guillaume Mourey, Claude Negrier, Philippe Nguyen, Placide Nyombe, Caroline Oudot, Brigitte Pan-Petesch, Benoît Polack, Anne Rafowicz, Antoine Rauch, Delphine Rivaud, Pascale Schneider, Alexandra Spiegel, Cecile Stoven, Brigitte Tardy, Marc Trossaërt, Jean-Baptiste Valentin, Stéphane Vanderbecken, Fabienne Volot, Annelise Voyer-Ebrard, Bénédicte Wibaut, Tanguy Leroy, Thomas Sannie, Hervé Chambost & Pascal Auquier. (2018) Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study. BMJ Open 8:7, pages e022409.
Crossref
Crossref
Ji Hyun Na, Ki Young Yoo, Ji Yoon Kim, Sang Kyu Park, Soon Ki Kim & Eun Jin Choi. (2018) Educational Interventions to Enhance Adherence to Prophylactic Treatment in Korean Hemophilia Patients. Clinical Pediatric Hematology-Oncology 25:1, pages 38-42.
Crossref
Crossref
Tom MunyerSheh-Li Chen & Amanda Cass. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.